Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06875973 · ClinicalTrials.gov registry record · Phase 3
Pelacarsen Roll-over Extension Program
A Phase 3 study of Atherosclerotic Cardiovascular Disease, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 599
- Enrollment target
- 20
- Study locations
NCT06875973: Recruiting Phase 3 study of Atherosclerotic Cardiovascular Disease, sponsored by Novartis Pharmaceuticals.
NCT06875973 is a Phase 3 study of Atherosclerotic Cardiovascular Disease that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 599 participants, below the 7,539-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06875973, a Phase 3 study of Atherosclerotic Cardiovascular Disease, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 599 participants
- Enrollment target
- 20
- Study locations
Study Summary
This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
Primary Outcome
Evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants with elevated Lp(a) and established atherosclerotic cardiovascular disease who have completed the parent study
Conditions Studied
Interventions
- DRUG Pelacarsen (TQJ230)
Study Locations (20)
Florida
- Excel Medical Clinical Trials LLC - Boca Raton
- C and A Clinical Trials - Cape Coral
- Proactive Clinical Research - Fort Lauderdale
- Proactive Clinical Research - Fort Lauderdale
- National Research Institute - Hialeah
- Sister Life Research Inc - Hialeah
- Zenith Clinical Research - Hollywood
- Columbus Clinical Services LLC - Miami
- Finlay Medical Research - Miami
- Infinite Clinical Research - Miami
California
- National Heart Institute - Beverly Hills
- Hope Clinical Research - Canoga Park
- Valley Clinical Trials Inc - Covina
- NICRs Research Center - Garden Grove
- Long Beach Clinical Trials - Long Beach
- Angel City Research Inc - Los Angeles
- California Medical Research Associates Inc - Northridge
- Stanford Health Care - Stanford
Alabama
- Parkway Medical Center - Birmingham
Arkansas
- Cardiology and Medicine Clinic PA - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2025-05-19 |
| Est. Completion | 2030-12-08 |
| Phase | Phase 3 |
What NCT06875973 shows while recruiting
NCT06875973 is an interventional study that assigns participants to a tested intervention. The registered 599 participants enrollment target is mid-sized for trials with a published cap, below the 7,539-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 1 intervention - of which Pelacarsen (TQJ230) is the first listed.
NCT06875973 names 20 study sites across 4 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06875973 about?
NCT06875973 is a clinical study titled "Pelacarsen Roll-over Extension Program". This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
What is the current status of trial NCT06875973?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 599 participants. The study started on 2025-05-19. Estimated completion is 2030-12-08.
What conditions does trial NCT06875973 study?
This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease.
What interventions are being tested in trial NCT06875973?
The interventions under investigation include: Pelacarsen (TQJ230) (DRUG).
Who is sponsoring clinical trial NCT06875973?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06875973 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerotic Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06875973's enrollment target sits among peer trials
599 11th of 21 higher than 11 of 21 other Atherosclerotic Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerotic Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Prevent Coronary Artery Disease Trial
RECRUITING · Phase 3
-
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
RECRUITING · Phase 3
-
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
-
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
ACTIVE NOT RECRUITING · Phase 3
-
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI